Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 9/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ACLY | P53396 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MRGPRX1 | Q96LB2 | 2/20 | 0.34 |
| ▸ | TSPO | P30536 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL872669 | 0.87 | TLR4 (0.54) | TLR4TP53ACLYSMN1; SMN2NPC1 | |
| SCHEMBL871909 | 0.87 | TLR4 (0.61) | TLR4TP53ACLYSMN1; SMN2NPC1 | |
| SCHEMBL871825 | 0.84 | TLR4 (0.66) | TLR4TP53ACLYSMN1; SMN2NPC1 | |
| SCHEMBL28159349 | 0.81 | TLR4 (0.58) | TLR4TP53ACLYSMN1; SMN2NPC1 | |
| SCHEMBL872918 | 0.81 | TLR4 (0.58) | TLR4TP53ACLYSMN1; SMN2NPC1 | |
| SCHEMBL1824250 | 0.81 | TLR4 (0.82) | TLR4TP53MRGPRX1TSPO | |
| SCHEMBL871429 | 0.81 | TLR4 (0.67) | TLR4TP53SMN1; SMN2NPC1POLB | |
| SCHEMBL872123 | 0.81 | TLR4 (0.82) | TLR4TP53MRGPRX1TSPO | |
| SCHEMBL871881 | 0.80 | TLR4 (0.66) | TLR4TP53SMN1; SMN2MRGPRX1TSPO | |
| SCHEMBL871637 | 0.79 | TLR4 (0.70) | TLR4TP53SMN1; SMN2MRGPRX1TSPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150203464-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-23 | — | — | US | disclosed |
| US-20120077856-A1 | PHARMACEUTICAL PRODUCT | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-03-29 | — | — | US | disclosed |
| EP-2366389-A1 | Severe sepsis preventive therapeutic agent | Takeda Pharmaceutical Company Limited (JP) | 2011-09-21 | — | — | EP | disclosed |
| US-20110184034-A1 | Severe sepsis preventive therapeutic agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-07-28 | — | — | US | disclosed |
| US-7960416-B2 | Oil-in-water emulsion of a 1-carboxylate-6-arylsulfamoyl cyclohexene and synthetic and naturally occurring phospholipids; nitric oxide or cytokine prodution inhibitors; cardiovascular disorders, autoimmune dieseases, septic shock; improved stability during autoclave sterilization | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20040063685-A1 | Cycloalkene antisepsis drug with antibacterial, antifungal, nonsteroidal antiinflammatory, steroid and/or anticoagulant agents | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063685-A1 | Cycloalkene antisepsis drug with antibacterial, antifungal, nonsteroidal antiinflammatory, steroid and/or anticoagulant agents | ELANE, MMP8, SERPINC1 | TLR4 567/4885TP53 4638/4885ACLY 2028/4885 |
| US-20150203464-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | PMP22, GAP43, NGF | TLR4 2222/4885TP53 791/4885ACLY 1904/4885 |
| US-20110184034-A1 | Severe sepsis preventive therapeutic agent | TLR1, TLR5, TLR4 | TLR4 3/4885TP53 3442/4885ACLY 3874/4885 |
| US-20120077856-A1 | PHARMACEUTICAL PRODUCT | ATF1, ATF4, TLR8 | TLR4 13/4885TP53 2716/4885ACLY 2316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.